TCI Peptide Therapeutics
2009
FOUNDED
PRIVATE
STATUS
1-10
EMPLOYEES
Grant
LATEST DEAL TYPE
$2.3M
LATEST DEAL AMOUNT
5
INVESTORS
Description
Developer of human drugs and intended to be used for treating cachexia. The company's drugs are melanocortin based peptide drugs for treating cardiovascular problems, enabling healthcare practitioners to modify peptides to perform better as drug candidates, with improved half-life, oral activity, and ability to cross the blood-brain barrier.
Website
Formerly Known As
Tensive Controls
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Primary Office
- 1601 South Providence Road
- Columbia, MO 65211
- United States
+1 (573) 000-0000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore TCI Peptide Therapeutics’s full profile, request a free trial.
TCI Peptide Therapeutics Valuation and Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Grant | 01-Sep-2016 | $2.3M | 00.00 | Completed | Generating Revenue | |
| 4. Later Stage VC (Series A) | 01-Jun-2016 | 00.00 | 00.00 | Completed | Generating Revenue | |
| 3. Grant | 01-Jan-2014 | 0000 | Completed | Generating Revenue | ||
| 2. Grant | 01-Jan-2012 | $1.75M | Completed | Generating Revenue | ||
| 1. Early Stage VC | Completed | Generating Revenue |
TCI Peptide Therapeutics Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Board Seat |
Contact Info |
|---|---|---|---|---|---|---|
| Centennial Investors | Angel Group | Minority | 000 0000 | 000000 0 | ||
| United States Department of Agriculture | Government | 000 0000 | 000000 0 | |||
| National Cancer Institute | Government | 000 0000 | 000000 0 | |||
| U.S. Department of Health and Human Services | Government | 000 0000 | 000000 0 | |||
| Missouri Technology | Venture Capital | Minority | 000 0000 | 000000 0 |